|
|
|
| Clinical Effect of Linezolid Combined with Cefotaxime Sodium in the Treatment of Neonatal Purulent Meningitis and its Effect on the Levels of Nerve Injury Factors,IL-12 and SAA in Children |
| CHEN Wei, DONG Zi-ran, WANG Qin-qin |
| Shangluo Central Hospital,Shangluo Shaanxi 726000 |
|
|
|
|
Abstract 【Objective】 To investigate the clinical effect of Linezolid combined with Cefotaxime sodium in the treatment of neonatal purulent meningitis and its effect on the levels of nerve injury factor, interleukin-12 (IL-12) and serum amyloid A (SAA). 【Methods】 The clinical data of 86 newborns with suppurative meningitis treated in our hospital were retrospectively analyzed. According to the different methods of medication, they were divided into observation group and control group, with 43 cases in each group. The control group was treated with cefotaxime sodium, and the observation group was treated with linezolid on the basis of the control group, both of which were treated for one week. The curative effects of the two groups were compared, including the levels of nerve injury factor [neuron specific enolase (NSE), S100β Protein], IL-12, SAA, cerebrospinal fluid protein content, total cell count, glucose level before and 1 week after treatment, and the incidence of adverse reactions was counted. 【Results】After one week of treatment, the total effective rate in the observation group was 95.35% (41/43), which was higher than 76.74% (33/43) in the control group, and the difference was statistically significant (P<0.05); The protein levels of serum IL-12,SAA, NSE and S100β in both groups were lower than those before treatmentin, and the observation group was lower than the control group (P<0.05) ; The protein content and total number of cells in cerebrospinal fluid of the two groups were lower than that before treatment, and the glucose level was higher than that before treatment. The difference between the observation group and the control group was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was 13.95% (6/43), lower than 6.98% (3/43) in the control group, but the difference was not statistically significant(χ2=0.49,P=0.48). 【Conclusion】Linezolid combined with Cefotaxime sodium is effective in the treatment of neonatal purulent meningitis, which can reduce inflammatory reaction, inhibit nerve injury, and has good safety.
|
|
Received: 13 September 2021
|
|
|
|
|
|
[1] CHEN B,ZHAI Q,OOI K,et al. Risk factors for hydrocephalus in neonatal purulent meningitis:a single-center retrospective analysis[J].J Child Neurol,2021,36(6):491-497.
[2] 彭林强,薛满,马春利,等.头孢噻肟钠联合酚妥拉明治疗重症肺炎疗效及对患儿肺功能、免疫功能、炎症因子水平的影响[J].陕西医学杂志,2019,48(11):1556-1559.
[3] 邹家齐,夏云.利奈唑胺耐药粪肠球菌的耐药机制与感染危险因素调查[J].中国感染与化疗杂志,2020,20(2):169-174.
[4] 江载芳,申昆玲,沈颖.诸福棠实用儿科[M].第8版.北京:人民卫生出版社,2015:912-918.
[5] WANG F,JIANG J,SHI G,et al. Anti-infective treatment of purulent meningitis caused by carbapenem-resistant Klebsiella pneumoniae in a newborn:a case report[J].Transl Pediatr,2020,9(5):713-719.
[6] 李静,杨赞章,闫晓静,等.氧化应激指标及S100B在低龄化脓性脑膜炎患儿病情严重程度评估中的价值[J].广东医学,2020,41(21):2196-2200.
[7] 张智勇,王精忠,朱舟.头孢噻肟钠联合万古霉素治疗小儿化脓性脑膜炎的临床研究[J].现代药物与临床,2019,34(7):2082-2086.
[8] 林素梅,吴朝波,吕聪,等.利奈唑胺治疗新生儿化脓性脑膜炎的疗效和安全性[J].新医学,2020,51(3):212-215.
[9] 王俊,文建国.儿童中枢神经系统感染脑脊液病原菌分布及耐药性分析[J].新乡医学院学报,2019,36(4):84-88.
[10] 胡爱星,李情操.血清淀粉样蛋白A、C反应蛋白和降钙素原联合检测在新生儿感染诊断中的应用[J].上海预防医学,2019,31(5):413-416.
[11] 岑臻,张丙宏.新生儿脐动脉血血清淀粉样蛋白A,C-反应蛋白水平变化及临床意义[J].中国妇幼保健,2019,34(7):1582-1585.
[12] 贺巧峰,苏乐,吴婷婷.血清PCT,CRP及NSE检测在小儿急性脑膜炎诊疗过程中的应用价值[J].河北医药,2020,42(22):69-71.
[13] 刘梅,王凤超,梅传忠,等.血清S100B蛋白和NSE在新生儿感染性脑损伤中的诊断价值[J].检验医学与临床,2019,16(9):1232-1234. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(6): 801-803. |
|
|
|
|
2022, Vol. 39 
